PVLA Palvella Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why PVLA matters now
Palvella Therapeutics, Inc. (PVLA) is a US stock in Healthcare. The latest InvestLog snapshot shows $144.76 with -4.16% on the session and $1.71B in market capitalization; recent performance reads 1-month +3.57% and YTD +8.05%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-15.8M, and EPS of $-1.20. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -2.2%.
The latest indexable market news headline is "Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $215.00; recent insider activity includes Korenberg Matthew E filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
6.37
P/S
0.00
EV/EBITDA
-30.99
DCF Value
$4.71
FCF Yield
-2.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-56.9%
ROA
-18.7%
ROIC
-17.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-15.8M | $-1.20 |
| Q4 2025 | $0.00 | $-12.7M | $-1.08 |
| FY 2025 | $0.00 | $-41.7M | $-3.71 |
| Q3 2025 | $0.00 | $-11.3M | $-1.03 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$225.00
Target (Median)
$215.00
Target Range
$205.00 - $255.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-0.14
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.